Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells

Gene Therapy

Volumn 19, Issue 11, 2012, Pages 1114-1120

  Cheadle, E J ^a   Rothwell, D G ^a   Bridgeman, J S ^a,b   Sheard, V E ^a   Hawkins, R E ^a   Gilham, D E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

B cell malignancies; CD2; Chimeric antigen receptor

Indexed keywords

CD19 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD48 ANTIGEN; CHIMERIC PROTEIN; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; B CELL LYMPHOMA; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD2; ANTIGENS, CD28; ANTIGENS, CD58; CELL LINE; HUMANS; INTERLEUKIN-2; LIGANDS; MICE; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84869091928     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.192     Document Type: Article

References (27)

1. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 2010; 16: 336-341.
2. Park JH, Brentjens RJ. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010; 9: 277-288.
3. Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 2010; 10: 77-90.
4. Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C et al. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptormediated target cell lysis. Cancer Res 2001; 61: 1976-1982. (Pubitemid 32692016)
5. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215-223.
6. Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother 2009; 32: 207-218.
7. Musgrave BL, Watson CL, Haeryfar SM, Barnes CA, Hoskin DW. CD2-CD48 interactions promote interleukin-2 and interferon-gamma synthesis by stabilizing cytokine mRNA. Cell Immunol 2004; 229: 1-12. (Pubitemid 39141130)
8. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L et al. Cre-loxregulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004; 101: 10380-10385. (Pubitemid 38924934)
9. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigendependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998; 188: 619-626. (Pubitemid 28387925)
10. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002; 20: 70-75.
11. Kato K, Koyanagi M, Okada H, Takanashi T, Wong YW, Williams AF et al. CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. J Exp Med 1992; 176: 1241-1249.
12. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007; 13: 5426-5435. (Pubitemid 47510370)
13. Krensky AM, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, Burakoff SJ. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol 1983; 131: 611-616. (Pubitemid 13079020)
14. Jacob MC, Agrawal S, Chaperot L, Giroux C, Gressin R, Le Marc'Hadour F et al. Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkin's lymphoma. Leukemia 1999; 13: 1428-1433. (Pubitemid 29429771)
15. Lee RV, Braylan RC, Rimsza LM. CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia. Am J Clin Pathol 2005; 123: 119-124. (Pubitemid 40066178)
16. Diederichsen AC, Stenholm AC, Kronborg O, Fenger C, Jensenius JC, Zeuthen J et al. Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers. Int J Cancer 1998; 79: 283-287. (Pubitemid 28262215)
17. Koretz K, Schlag P, Moller P. Sporadic loss of leucocyte-function- associated antigen-3 (LFA-3) in colorectal carcinomas. Virchows Arch A Pathol Anat Histopathol 1991; 419: 389-394.
18. Mayer B, Lorenz C, Babic R, Jauch KW, Schildberg FW, Funke I et al. Expression of leukocyte cell adhesion molecules on gastric carcinomas: possible involvement of LFA-3 expression in the development of distant metastases. Int J Cancer 1995; 64: 415-423. (Pubitemid 26051676)
19. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116: 3875-3886.
20. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 2010; 184: 6938-6949.
21. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267. (Pubitemid 26119138)
22. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
23. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988; 62: 1120-1124. (Pubitemid 18082924)
24. Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 2010; 184: 1885-1896.
25. Cheadle EJ, Gilham DE, Hawkins RE. The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established Bcell lymphoma. Br J Haematol 2008; 142: 65-68. (Pubitemid 351783147)
26. Jacks T. The pSico and pSicoR Information Page. Massachusetts Institute of Technology, http://web.mit.edu/jacks-lab/protocols/pSico.html.
27. Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, Lehane M et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother 2002; 25: 139-151. (Pubitemid 34260765)